



(Formerly Known as Adi Rasayan Limited)
CIN : L24231MH1992PLC323914

104 & 105 1st Floor Gundecha Industrial Premises Co-op Soc.
Ltd. Akurli Road Kandivali East Mumbai - 400101

+91- 86555 50242

compliance@genpharmasec.com
info@genpharmasec.com

www.genpharmasec.com

Date:- 27th June, 2020

To,
Department of Corporate Services,
BSE LIMITED
P. J. Towers, Dalal Street,
Mumbai - 400 001.

Dear Sir/ Madam,

Subject:- Outcome of Board Meeting held on Saturday, 27th June, 2020

Ref: BSE Scrip Code: 531592.

Pursuant to the provisions of Regulation 30 (2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform your good self that the Board of Directors of our Company in their meeting held on Saturday, 27th June, 2020 has:

1. Considered and Approved and taken on records the Audited Financial Results along with the Statement of Assets and Liabilities and the Audit Report for the quarter and Financial Year ended on March 31, 2020 as recommended by the Audit Committee.

Pursuant to the provisions of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby enclose the following:

- a. Audited Financial Results along with the Statement of Assets and Liabilities for the Quarter and Financial Year ended on March 31, 2020;
- b. Audit Report from the Statutory Auditor of the Company.

The report of the Auditor is with unmodified opinion with respect to the Audited Financial Results of the Company for the Quarter and the Financial Year ended March 31, 2020.

2. Considered and approved the appointment of M/s. Jaymin Modi & Co, Practicing Company Secretary as the Secretarial Auditor of the Company for financial year 2020-2021.



3. Considered and taken on records the Annual Disclosure of interest received from the Director of the Company upon the closure of the financial year.
4. Considered and approved the appointment of M/s. Meenakshi Manish Jain & Associates, Chartered Accountants, as an Internal Auditor of the Company for financial year 2020-2021.
5. Re-appointed of Mrs. Amisha Dani (DIN: 07265134), as an Independent Director of the company (whose current tenure will come to an end on August 13, 2020) for a period of 5 year with effect from 14th August, 2020 to August 13, 2025, and is not liable to retire by rotation subject to approval of members at ensuing general meeting, pursuant to applicable provisions of Companies Act, 2013 read with the Rules issued thereunder and SEBI Regulations. The brief profile is attached as annexure.

Kindly take the same on your records.

Thanking You,

Yours Truly,

For Generic Pharmasec Limited
(Formerly known as Adi Rasayan Limited)


Dollar Chheda
Director
DIN: 08490484



Annexure

Details under Regulation 30 of SEBI (LODR) Regulations, 2015 read along with SEBI circular CIR/CFD/CMD/4/2015 dated September 09, 2015.

Mrs. Amisha Dani	
Reason for change viz. appointment, resignation, removal, death or otherwise	Re-appointed Mrs. Amisha Dani (DIN: 07265134), as an Independent Director of the company (whose current tenure will come to an end on August 13, 2020) for a second term w.e.f 14.08.2020.
Date of appointment/cessation (as applicable) & term of appointment	w.e.f 14 th August 2020
Brief profile (in case of appointment)	Mrs. Amisha Dani has more than 10 years of experience in field of Administration. She has been on the Board of our Company since 2015. As an Independent Director of our Company with corporate acumen she brings value addition to our Company.
Disclosure of relationships between Directors (in case of appointment as a Director)	Mrs. Amisha Dani is not related to any Director who are on the Board of the Company as on the date of her appointment



GENERIC PHARMASEC LIMITED
Formerly known as ADI RASAYAN LTD
Statement of Standalone Audited Results for the Quarter and Year Ended March 31, 2020

(Rs. In Lakhs)

Particulars	Standalone				
	Quarter Ended			Year Ended	
	31/03/2020 (Audited)	31/12/2019 (Unaudited)	31/03/2019 (Audited)	31/03/2020 (Audited)	31/03/2019 (Audited)
1 Revenue from Operations	570.44	248.41	-	1,650.13	37.51
2 Other Income	8.46	18.10	19.99	56.28	37.50
3 Total Revenue (1 + 2)	578.90	266.51	19.99	1,706.41	75.01
4 Expenses					
Cost of materials consumed	-	-	-	-	-
Purchase of stock-in-trade	567.15	244.29	525.00	1,344.64	525.00
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(58.19)	(19.97)	(525.00)	179.00	(525.00)
Employee benefits expense	3.97	4.26	0.43	12.92	1.70
Depreciation and amortisation expense	0.16	0.14	0.01	0.49	0.02
Other expenses	18.61	9.11	9.95	48.84	44.53
Total expenses	531.70	237.83	10.38	1,585.88	46.26
5 Profit/(Loss) Before Exceptional Item and Tax (3-4)	47.21	28.68	9.62	120.54	28.75
6 Exceptional items	-	-	-	-	-
7 Profit/(Loss) Before Tax (5-6)	47.21	28.68	9.62	120.54	28.75
8 Tax expense					
(1) Current Tax	(1.67)	18.33	5.65	(20.00)	5.65
(2) Deferred Tax	0.40	-	(0.01)	0.40	(0.01)
9 Profit / (Loss) from continuing operations (7 - 8)	45.94	10.34	3.97	100.94	23.11
10 Profit / (Loss) from discontinuing operations	-	-	-	-	-
11 Tax expense of discontinuing operations	-	-	-	-	-
12 Profit/(loss) from Discontinuing operations (after tax)	-	-	-	-	-
13 Profit (Loss) for the period (9+12)	45.94	10.34	3.97	100.94	23.11
14 Other Comprehensive Income;					
A (I) Items that will not be reclassified to profit or loss	(92.21)	(18.44)	(63.68)	(358.33)	(61.58)
(II) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
B (I) Items that will be reclassified to profit or loss	-	-	-	-	-
(II) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
15 Total Comprehensive Income for the period (13+14) (Comprising profit/ (loss) and other Comprehensive Income for the period	(46.27)	(8.10)	(59.70)	(257.40)	(38.47)
16 Earnings per equity share (for discontinued & continuing operations) of face value of Rs. 10 each (Refer Note. 6)					
(a) Basic	0.02	0.02	0.00	0.05	0.12
(b) Diluted	0.00	0.02	0.00	0.02	0.12

Notes:

- The above result were reviewed by the Audit Committee and approved by the Board Of directors at their meeting on 27th June, 2020. In terms of SEBI circular CIR/CFD/CMD/56/2016 dated 28th May, 2016, the Company declares that the statutory auditors have issued Audit Report with an unmodified opinion.
- The above result have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act 2013, and other recognized accounting practices and policies to the extent applicable.
- The figures for the quarter ended March 31, 2020 and March 31, 2019, as reported in the financial results, are the balancing figures between audited figures in respect of the full financial year and the unaudited published year to date figures upto the end of third quarter of the financial year ended 31.03.2020 and 31.03.2019 respectively. Also, the figures upto the end of the third quarter had only been reviewed and not subjected to audit.
- During the quarter ended March 31, 2020, the outbreak of the coronavirus disease of 2019 (COVID-19) spread throughout the world and became a global pandemic. On 25th March, 2020, the Government of India ordered lockdown throughout the country, but since the company operates in pharmaceutical activities the pandemic does not have any material adverse effect on its business operations. The company has followed the safety guidelines as suggested by Government during the business operations during lockdown and after resumption of lockdown. However, management believes that it has taken into account all the possible impacts known events arising from COVID-19 pandemic and the resultant lockdowns in the preparation of financial results including but not limited to its assessment of company's liquidity and going concern, recoverable values of trade receivables, and other assets. We cannot fully estimate the accurate future impact of COVID-19 on our operations but we can say that it may affect the future profitability and revenue and the management will be ensuring that the business operations are carried out smoothly. The above parameters are contingent as it may and may not happen & the company will provide regular updates as and when in any situation any major changes occur.
- Previous period figures have been regrouped/reclassified as considered necessary to facilitate comparison.
- The Company operates in a single segment in terms of Ind AS 108.

PLACE : MUMBAI
DATE : 27.06.2020



For and on behalf of the Board of
GENERIC PHARMASEC LIMITED
(Formerly known as ADI RASAYAN LTD)

Dollar

DOLLAR CHHEDA
Director
DIN No. 08490484

GENERIC PHARMASEC LIMITED

(Formerly known as ADI RASAYAN LTD)

STATEMENT OF ASSETS & LIABILITIES AS AT 31ST MARCH, 2020

(Rs. In Lakhs)

Particulars	As At 31st March 2020	As At 31st March 2019
Assets		
(1) Non-current assets		
(a) Property, plant and equipment	4.83	0.07
(b) Stock in Trade	346.00	525.00
(i) Investments	347.60	604.90
(ii) Loans	534.45	265.33
(b) Deferred Tax Asset (Net)	0.41	0.01
Total non-current assets	1,233.30	1,395.32
(2) Current assets		
(a) Financial assets		
(i) Investments	228.45	148.08
(ii) Cash and Cash equivalents	257.84	520.00
(iii) Loans	703.33	3.60
(v) Others	6.00	0.50
(b) Current Tax assets	-	7.46
(c) Other Current Asset	46.81	95.03
Total current assets	1,242.43	774.67
Total assets	2,475.73	2,169.99
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	2,168.60	2,168.60
(b) Other Equity	(265.13)	(7.43)
Total of Equity	1,903.46	2,161.17
Liabilities		
(1) Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	-	-
Total non-current liabilities	-	-
(2) Current Liabilities		
(a) Financial Liabilities		
(i) Trade Payables	554.14	0.87
(b) Other Current Liabilities	3.52	0.85
(c) Current Tax liabilities	14.60	7.10
Total current liabilities	572.27	8.82
Total equity and liabilities	2,475.73	2,169.99
	(0.00)	-

For and on behalf of the Board of
GENERIC PHARMASEC LIMITED

(Formerly known as ADI RASAYAN LTD)



Dollar

DOLLAR CHHEDA

Director

DIN No. 08490484

Place: Mumbai

DATE : 27.06.2020

GENERIC PHARMASEC LIMITED

(Formerly known as ADI RASAYAN LIMITED)

Cash Flow Statement as at 31.03.2020

(Rs. In Lakhs)

PARTICULARS	For the year ended 31st March 2020	For the year ended 31st March 2019
A CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit /(Loss) before tax and Extra Ordinary items	120.54	28.75
<u>Adjustment for:-</u>		
Depreciation	0.49	0.02
Profit on sale of Investment	0.59	(2.23)
Interest Income	(54.95)	(35.26)
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	66.67	(8.71)
<u>Adjustment for:-</u>		
(Increase)/decrease Trade and Other Receivables	(699.74)	(3.60)
Increase/(decrease) Trade Payables	553.27	0.73
Increase/(decrease) Other Current Liabilities	2.67	(1.32)
(Increase)/decrease in Inventories	179.00	(525.00)
(Increase)/decrease Others Current Assets	42.72	(95.53)
CASH GENERATED FROM OPERATIONS	77.92	(624.72)
Direct Taxes Paid	(5.71)	(5.93)
Last Year Direct Taxes Paid	0.37	(1.13)
I NET CASH FLOW FROM OPERATING ACTIVITIES	139.25	(640.49)
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(5.24)	-
New Investments	(415.08)	(1,218.45)
Proceeds from sale of investment	233.09	593.62
Investment in equity warrants	-	(187.50)
Investment in equity shares	-	-
Loans Given/ Repayments received (Net)	(269.12)	(265.33)
Interest Income	54.95	35.26
II NET CASH USED IN INVESTING ACTIVITIES	(401.41)	(1,042.40)
C CASH FLOW FROM FINANCING ACTIVITIES		
Preceeds from Issue of Share Capital	-	2,136.00
Preceeds from Issue of Share Warrants	-	150.00
Preceeds from Long Term Borrowings	-	(98.80)
III NET CASH USED IN FINANCING ACTIVITIES	-	2,187.20
NET INCREASE/(DECREASE) IN CASH OR CASH EQUIVALENTS (I + II + III)	(262.16)	504.31
Add:- CASH & CASH EQUIVALENTS AS AT BEGNNING	520.00	15.69
CLOSING BALANCE OF CASH & CASH EQUIVALENTS	257.84	520.00
	-	-

For and on behalf of the Board
GENERIC PHARMASEC LIMITED

D. L. Chheda
D. L. LAR CHHEDA
Director
DIN No. 08490484

Place: Mumbai
DATE : 27.06.2020



INDEPENDENT AUDITOR'S REPORT

To
The Board of Directors
Generic Pharmasec Limited

Report on the audit of the Standalone Financial Results

Opinion

We have audited the accompanying statement of financial results of Generic Pharmasec Limited for the quarter and year ended 31st March, 2020 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations")

In our opinion and to the best of our information and according to the explanations given to us these financial results:

(i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and

(ii) give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information for the quarter ended as well as for the year to date results for the period from 1.4.2019 to 31.03.2020

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those Standards are further described in the auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the Company in accordance with the code of ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the code of ethics.



Emphasis of Matter

We invite attention to Note No. 4 to the Standalone Financial Results regarding uncertainties associated with the COVID-19 pandemic and impact assessment made by the company on the Standalone Financial Results. As mentioned in the said note, based on the future economic conditions, the actual impact may not be in line with the current estimates as made by the company, although the current impact assessment does not indicate any adverse impact on the ability of the company to continue as a going concern.

Our opinion on the Standalone Financial Results is not modified in respect of this matter.

Management's responsibility for the Standalone Financial Results

These quarterly financial results as well as the year to date standalone financial results have been prepared on the basis of the interim financial statements. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of the net profit/loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, 'Interim Financial Reporting' prescribed under Section 133 of the Act read with relevant rules issued thereunder and other Accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial result that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of directors are also responsible for overseeing the Company's financial reporting process.

Auditor's responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the operating effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of Board of Director's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matters

Attention is drawn to the fact that figures for the quarter ended 31st March, 2020 as reported in the Financial Results are the balancing figures between audited figures in respect of the financial year ended 31st March, 2020 and the published year to date figures upto the end of the third quarter of the relevant financial year. Also the figures upto the end of the third quarter are only been reviewed and not subjected to audit.

For Koshal & Associates

Firm Reg.No.121233W

Koshal Maheshwari
Proprietor
M.No.043746



Place of signature: Mumbai

Date: 27th June, 2020

UDIN: 20043746AAAABI2003



(Formerly Known as Adi Rasayan Limited)
CIN : L24231MH1992PLC323914

104 & 105 1st Floor Gundecha Industrial Premises Co-op Soc.
Ltd. Akurli Road Kandivali East Mumbai - 400101
+91- 86555 50242
compliance@genpharmasec.com
info@genpharmasec.com
www.genpharmasec.com

Date: 27/06/2020

To,
The Department of Corporate Services,
Bombay Stock Exchange Limited
14th Floor, P.J. Towers,
Dalal Street, Mumbai - 400 001.

Dear Sir/ Madam,

Sub :- Declaration w.r.t. Audit Report with unmodified opinion to the Audited Financial Results for the Financial Year ended 31st March, 2020 .

Ref: BSE Scrip Code: 531592

Pursuant to Regulation 33(3) (b) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015, we hereby confirm that the Statutory Auditors of the Company M/s Koshal & Associates, Chartered Accountants, Statutory Auditors of the Company have issued an Audit Report with unmodified opinion on Standalone Audited Financial Results of the Company for the Quarter and year ended 31st March, 2020.

The Declaration is given in compliance to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended by SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulation 2016 vide notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May 25, 2016 and circular no CIR/CFD/CMD/56/2016 dated May 27, 2016.

Kindly take the same on records and acknowledge the receipt of the same.

Thanking You,

Yours Truly,

For **GENERIC PHARMASEC LIMITED**
(Formerly Known as Adi Rasayan Limited)

Dollar
Mr. Dollar Chheda
Director
DIN: 08490484

